Emyria Limited (EMD.XA)

0.0540 -0.0030 (-5.26%) At close: 10:15AM AEST

Emyria Limited

D2, 661 Newcastle Street
Leederville, WA 6007
Australia
61 8 6559 2800
https://emyria.com

Sector(s): 
Industry: 
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Michael Winlo	MD & Director	421.04k	N/A	N/A
Dr. Alistair Vickery	Executive Medical Director & Director	381.42k	N/A	N/A
Mr. Joseph Daniel Ohayon ACA, MBA Intl Bus.	Chief Financial Officer	N/A	N/A	N/A
Ms. Sara Polanski	Communications & Brand Manager	N/A	N/A	N/A
Ms. Tracie Ernenwein	Head of Research & Drug Development	N/A	N/A	N/A
Mary-Ann Rennie	Head of Corporate Operations	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops psychedelic-assisted therapy, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and mild stress and anxiety. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.

Corporate Governance

Emyria Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.